The True Potential of Hemp: What the Future Holds
From the very start of cannabis stigmatisation and prohibition, hemp was unfairly lumped into the same category as 'marijuana,' 'weed,' or even the evocative 'ganja,’
Use our chat feature to speak with one of our expert consultants who can help you identify if medical cannabis can help you.
Stay updated with the latest trends, news, and developments in the UK medical cannabis industry, from regulations to market growth and innovations.
From the very start of cannabis stigmatisation and prohibition, hemp was unfairly lumped into the same category as 'marijuana,' 'weed,' or even the evocative 'ganja,’
Every year on the 23rd of January, National Reading Day is recognised - a campaign to encourage a lifelong habit of reading from childhood to adulthood.
In December 2024, Releaf’s website attracted 9510 daily visits and nearly 1,000 page views an hour. In this blog we break down the data, and evaluate why thousands trust our reliable content about medical cannabis in the UK.
As the first medical cannabis clinic in the UK to provide their patients with medical cannabis cards, at Releaf we’re often asked ‘what's the difference between Releaf’s medical cannabis cards and Cancard?’ - and, we’re here to clear up the confusion.
Almost a year after launching, the Cannabis Industry Council’s ‘Yes We Can’ research report was published, revealing what UK based medical cannabis patients think about various aspects of the medical cannabis industry. Here, we take a look at what they found, and, what this could mean.
The Food Standards Agency (FSA)— the body responsible for the regulation of consumer CBD products in the UK—has hinted at ambitious new targets for CBD products in the UK market, which could see a push for zero detectable THC levels.
At Releaf, one of our core commitments is to provide accurate, reliable and relevant information about medical cannabis treatments here in the UK, and in order to do this we’ve conducted our own research on numerous occasions.
Cannabis-based medicinal products (CBMPs) are now prescribed in a variety of forms in the UK. But one product type you won’t find in the formulary is cannabis resin.
At Releaf, our mission is to enhance the quality of life of individuals across the UK by giving them back control of their health. And throughout 2024, as well as providing patient-focused care and unwavering support through our expert clinical and patient support teams, we’ve had the privilege of speaking with our patients one on one to find out more about their health journeys.
Along with adapting to a whole new treatment option, patients just starting with medical cannabis treatment can sometimes find themselves feeling a little inundated by the terminology, acronyms, and jargon that accompany their treatment plan. One of the key terms for new patients to get their head around is MDT: Multidisciplinary Team.
Explore the potential of medical cannabis in 2025 as an alternative healthcare option in the UK. Learn how Releaf helps patients address health concerns like anxiety, chronic pain, and more with personalised, patient-centred treatment plans. Discover the benefits, conditions eligible for treatment, and how to take the first step toward a healthier you this New Year.
While most people look for alternative treatment options because conventional medicines haven’t met their needs, an increase in prescription drug shortages in the UK is leaving more patients without access to effective medications.
With extended families coming together and immediate families typically spending long periods of time together over the Christmas period, catching up on what everyone has been up to over the last year is a common course conversation takes.
With UK medical cannabis going nothing short of viral in the past 12 months or so (and patient numbers climbing at an exponential rate), the need for clear, concise information regarding medical cannabis accessories has never been more obvious.
Growing awareness and acceptance of cannabis-based products has been on the rise in recent years. In addition to a flourishing CBD consumer market, medical cannabis has become increasingly accessible to patients with a variety of health concerns.
This year, we’ve taken a leaf from Spotify’s book and put together a collection of our favourite moments during 2024. As the year draws to a close, here we reflect on our milestones, growth, and most importantly, the transformative difference we’re making for patients.
With the holiday season less than two weeks away, we want to make sure each and every Releaf patient is well-prepared for the slight changes to our normal operating schedule - and the minor adjustments to medication delivery during this year's festive period.
The holiday season is fast approaching, and with it, the yearly yearning to pack your bags, hit the road and hopefully escape the winter blues.
The days are drawing in and Christmas is right around the corner. Many of us will be working our way down Christmas lists, trying to find the perfect presents for our loved ones.
Around the world, 1.3 billion, or 1 in 6, people live with a disability - yet many face barriers when accessing adequate healthcare services. At Releaf, it's important to us to participate in events like International Day of Persons with Disabilities, and so that’s exactly what we’re doing.
Last year, our representative research found 68% of UK adults would consider medical cannabis treatment if their doctor recommended it, but around 1 in 4 said they would be apprehensive about, and perhaps discouraged by, the costs involved.
There has been a huge resurgence in interest in plant-based health solutions in the past few decades. Not so long ago, most patients would just take whatever pharmaceutical options their GPs prescribed - but as we mature as a society and our collective understanding of alternative medicine grows, the understanding that plants can offer natural relief from a huge range of symptoms grows.
Disability History Month, taking place from 14 November— 20 December highlights the history of the equality and human rights struggles of disabled individuals in the UK.
As new findings from an early health economic analysis suggest that prescribing medical cannabis on the NHS to treat chronic pain could save the state healthcare provider almost £4 billion every year, we take a closer look at the research.